Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Hoppe

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Antiviral Therapy|October 13, 2017
HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in AfricaAnne Hoppe, Marina Giuliano, Abbas Lugemwa, et al.
The American Journal of Tropical Medicine and Hygiene|February 25, 2025
Feasibility and Acceptability of SARS-CoV-2 Antigen Rapid Diagnostic Testing in High-Risk Markets and Trade Hubs in Kampala, UgandaIsaac Ssewanyana, Sam Acellam, Martha Ampumuza, et al.
The Lancet. HIV|May 13, 2017
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trialNicholas I Paton, Cissy Kityo, Jennifer Thompson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 28, 2017
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan AfricaCissy Kityo, Jennifer Thompson, Immaculate Nankya, et al.
The American Journal of Tropical Medicine and Hygiene|December 10, 2024
Consecutive Evaluation of Systematic Community-Based COVID-19 Antigen Rapid Diagnostic Testing in Three Different Populations in Jamaica during the COVID-19 PandemicDavid Walcott, Chika Ozongwu, Carl Bruce, et al.
The New England Journal of Medicine|July 21, 2021
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.
The Journal of Pediatrics|August 10, 2010
A hospital-based intermittent nocturnal hemodialysis program for children and adolescentsAnne Hoppe, Christina von Puttkamer, Ursula Linke, et al.
The American Journal of Tropical Medicine and Hygiene|October 21, 2024
Use of Antigen Rapid Diagnostic Test for Detection of COVID-19 Cases in University Settings in CameroonChavely Gwladys Monamele, Landry Messanga, Nicolas Njintang Yanou, et al.
The American Journal of Tropical Medicine and Hygiene|October 15, 2024
Uptake, Acceptability, and Results of SARS-CoV-2 Antigen Rapid Diagnostic Testing in Community Settings in CameroonTatiana K Djikeussi, Boris Kevin Tchounga, Loic Feuzeu, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Antiviral Therapy|October 13, 2017
HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in AfricaAnne Hoppe, Marina Giuliano, Abbas Lugemwa, et al.
The American Journal of Tropical Medicine and Hygiene|February 25, 2025
Feasibility and Acceptability of SARS-CoV-2 Antigen Rapid Diagnostic Testing in High-Risk Markets and Trade Hubs in Kampala, UgandaIsaac Ssewanyana, Sam Acellam, Martha Ampumuza, et al.
The Lancet. HIV|May 13, 2017
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trialNicholas I Paton, Cissy Kityo, Jennifer Thompson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 28, 2017
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan AfricaCissy Kityo, Jennifer Thompson, Immaculate Nankya, et al.
The American Journal of Tropical Medicine and Hygiene|December 10, 2024
Consecutive Evaluation of Systematic Community-Based COVID-19 Antigen Rapid Diagnostic Testing in Three Different Populations in Jamaica during the COVID-19 PandemicDavid Walcott, Chika Ozongwu, Carl Bruce, et al.
The New England Journal of Medicine|July 21, 2021
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.
The Journal of Pediatrics|August 10, 2010
A hospital-based intermittent nocturnal hemodialysis program for children and adolescentsAnne Hoppe, Christina von Puttkamer, Ursula Linke, et al.
The American Journal of Tropical Medicine and Hygiene|October 21, 2024
Use of Antigen Rapid Diagnostic Test for Detection of COVID-19 Cases in University Settings in CameroonChavely Gwladys Monamele, Landry Messanga, Nicolas Njintang Yanou, et al.
The American Journal of Tropical Medicine and Hygiene|October 15, 2024
Uptake, Acceptability, and Results of SARS-CoV-2 Antigen Rapid Diagnostic Testing in Community Settings in CameroonTatiana K Djikeussi, Boris Kevin Tchounga, Loic Feuzeu, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
Pageof 4